Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)
Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm) . (MENAFN - EIN Presswire) 
 
  52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108968691/Cogent-Biosciences-Announces-Positive-Updated-Data-From-Ongoing-Phase-2-APEX-Trial-Evaluating-Bezuclastinib-In-Patients-With-Advanced-Systemic-Mastocytosis-Advsm
2024-12-08
rss
(MENAFN - EIN Presswire) 
 
  52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median ...
Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib In Patients With Advanced Systemic Mastocytosis (Advsm)